<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064154</url>
  </required_header>
  <id_info>
    <org_study_id>02117</org_study_id>
    <nct_id>NCT01064154</nct_id>
  </id_info>
  <brief_title>Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study of Dr. Reddys Under Fasting Conditions</brief_title>
  <official_title>Randomized,2-way Crossover, Bioequivalence Study of Carvedilol 25 mg Film-coated Tablets and COREG® 25 mg Film-coated Tablets Administered as 1 x 25 mg Film-coated Tablet in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carvedilol 25 mg Film-coated Tablets, Bioequivalence Study Of Dr. Reddys Under Fasting&#xD;
      Conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized,two-way Crossover, Bioequivalence Study of Carvedilol 25 mg Film-coated Tablets&#xD;
      and COREG® 25 mg Film-coated Tablets Administered as 1 x 25 mg Film-coated Tablet in Healthy&#xD;
      Subjects Under Fasting Conditions.&#xD;
&#xD;
      Treatment Duration: Single dose of the two treatments (A, B) in two different occasions,&#xD;
      separated by a washout period of 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">May 2002</completion_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carvedilol Tablets, 25 mg Bioequivalence Study Of Dr Reddys under fasting condition</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coreg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coreg Tablets 25 mg of GlaxoSmithKline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Carvedilol Tablets 25 mg</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_label>Coreg</arm_group_label>
    <other_name>Coreg Tablets 25 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects enrolled in this study will be members of the community at large. The recruitment&#xD;
        advertisements may be done using different media (e.g. radio, newspaper, Anapharm Inc.&#xD;
        Website, Anapharm Inc. volunteers' data base). Subjects must meet all of the following&#xD;
        criteria in order to be included in the study:&#xD;
&#xD;
          -  Subjects will be females and/or males, smokers and non-smokers, 18 years of age &amp;&#xD;
             older.&#xD;
&#xD;
          -  Female subjects will be post-menopausal/surgically sterilized.&#xD;
&#xD;
               -  Post-menopausal status is defined as absence of menses for the past 12 months or&#xD;
                  hysterectomy with bilateral oophorectomy at least 6 months ago.&#xD;
&#xD;
               -  Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal&#xD;
                  ligation at least 6 months ago.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects to whom any of the following applies will be excluded from the study:&#xD;
&#xD;
          -  Clinically significant illnesses/surgery within 4 weeks prior to the administration of&#xD;
             study medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Subjects with a clinically significant history of second- or third-degree AV block,&#xD;
             sick sinus syndrome or severe bradycardia or in patients with cardiogenic shock who&#xD;
             have decompensated heart failure.&#xD;
&#xD;
          -  Subjects with history of hepatic failure.&#xD;
&#xD;
          -  Presence or history of liver disease, cardiovascular disease, diabetes,&#xD;
             hyperthyroidism aDd peripheral vascular disease.&#xD;
&#xD;
          -  Positive urine drug screen or positive testing for hepatitis B, hepatitis C or HIV at&#xD;
             screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure &lt;ll0 or over 140 mmHg, or diastolic blood pressure &lt;70 or over 90 mmHg; or&#xD;
             heart rate &lt;60 or over 100 bpm) at screening.&#xD;
&#xD;
          -  Subjects with BMI ≥30.0.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than fourteen units of alcohol per week (1 Unit&#xD;
             = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%).&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)&#xD;
             within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine&#xD;
             (PCP) and crack) within 1 year of the screening visit.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             medical subinvestigator, contraindicates the subject's participation in this study.&#xD;
&#xD;
          -  History of allergic reactions to carvedilol or other beta-blocking agents (e.g.&#xD;
             propranolol, labetalol, acebutolol, atenolol, esmolol, metoprolol, oxprenolol,&#xD;
             timolol, pindolol, betaxolol, levobunolol and nadolol).&#xD;
&#xD;
          -  History of pulmonary or bronchospastic disease (including asthma).&#xD;
&#xD;
          -  Subjects with pheochromocytoma.&#xD;
&#xD;
          -  History of allergic reactions to heparin.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin;&#xD;
             examples of inhibitors: antidepressants, cimetidine, diltiazem,&#xD;
             erythromycin,ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine), use of&#xD;
             an investigational drug or participation in an investigational study within 30 days&#xD;
             prior to administration of the study medication.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products (including natural products, vitamins, garlic&#xD;
             as supplement) within 7 days prior to administration of study medication, except for&#xD;
             topical products without systemic absorption.&#xD;
&#xD;
          -  Subjects who have had a depot injection or an implant of any drug 3 months prior to&#xD;
             administration of study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to&#xD;
             administration of the study medication as follows:&#xD;
&#xD;
          -  less than 300 mL of whole blood within 30 days or&#xD;
&#xD;
          -  300 mL to 500 mL of whole blood within 45 days or&#xD;
&#xD;
          -  more than 500 mL of whole blood within 56 days.&#xD;
&#xD;
          -  Smoking more than 25 cigarettes per day.&#xD;
&#xD;
          -  Subjects who have consumed food or beverages containing grapefruit (e.g. fresh,&#xD;
             canned,or frozen) within 7 days prior to administration of the study medication.&#xD;
&#xD;
        Additional exclusion criteria for females only:&#xD;
&#xD;
        • Breast-feeding subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Bircell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm Inc, Canada, GIV 2K8</affiliation>
  </overall_official>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <last_update_submitted>February 4, 2010</last_update_submitted>
  <last_update_submitted_qc>February 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Assistanct Manager - Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

